File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients

TitleDouble blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients
Authors
Issue Date2002
PublisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
Citation
Gut, 2002, v. 51 n. 4, p. 502-506 How to Cite?
AbstractBackground: The use of proton pump inhibitors for the treatment of functional dyspepsia is controversial and the role of Helicobacter pylori infection in functional dyspepsia is uncertain. Aim: To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Method: Patients with a clinical diagnosis of functional dyspepsia according to the Rome II criteria and normal upper gastrointestinal endoscopy were recruited and randomised to receive: (1) lansoprazole 30 mg, (2) lansoprazole 15 mg, or (3) placebo, all given daily for four weeks. Dyspepsia symptom scores and quality of life (SF-36 score) were evaluated before and four weeks after treatment. Results: A total of 453 patients were randomised. There was no difference in the proportion of patients with complete symptom relief in the lansoprazole 30 mg (23%) and lansoprazole 15 mg (23%) groups compared with the placebo group (30%). The proportion of H pylori positive patients with a complete response was similar with lansoprazole 30 mg (34%) and lansoprazole 15 mg (20%) versus placebo (22%). All symptom subgroups (ulcer-like, dysmotility-like, reflux-like, and unspecified dyspepsia) had similar proportions of patients with complete symptom relief after treatment. Conclusion: Proton pump inhibitor treatment is not superior to placebo for the management of functional dyspepsia in Chinese patients.
Persistent Identifierhttp://hdl.handle.net/10722/43105
ISSN
2015 Impact Factor: 14.921
2015 SCImago Journal Rankings: 6.474
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, WMen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorHung, WKen_HK
dc.contributor.authorYee, YKen_HK
dc.contributor.authorYip, AWCen_HK
dc.contributor.authorSzeto, MLen_HK
dc.contributor.authorFung, FMYen_HK
dc.contributor.authorTong, TSMen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorHu, WHCen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLam, SKen_HK
dc.date.accessioned2007-03-23T04:38:57Z-
dc.date.available2007-03-23T04:38:57Z-
dc.date.issued2002en_HK
dc.identifier.citationGut, 2002, v. 51 n. 4, p. 502-506en_HK
dc.identifier.issn0017-5749en_HK
dc.identifier.urihttp://hdl.handle.net/10722/43105-
dc.description.abstractBackground: The use of proton pump inhibitors for the treatment of functional dyspepsia is controversial and the role of Helicobacter pylori infection in functional dyspepsia is uncertain. Aim: To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Method: Patients with a clinical diagnosis of functional dyspepsia according to the Rome II criteria and normal upper gastrointestinal endoscopy were recruited and randomised to receive: (1) lansoprazole 30 mg, (2) lansoprazole 15 mg, or (3) placebo, all given daily for four weeks. Dyspepsia symptom scores and quality of life (SF-36 score) were evaluated before and four weeks after treatment. Results: A total of 453 patients were randomised. There was no difference in the proportion of patients with complete symptom relief in the lansoprazole 30 mg (23%) and lansoprazole 15 mg (23%) groups compared with the placebo group (30%). The proportion of H pylori positive patients with a complete response was similar with lansoprazole 30 mg (34%) and lansoprazole 15 mg (20%) versus placebo (22%). All symptom subgroups (ulcer-like, dysmotility-like, reflux-like, and unspecified dyspepsia) had similar proportions of patients with complete symptom relief after treatment. Conclusion: Proton pump inhibitor treatment is not superior to placebo for the management of functional dyspepsia in Chinese patients.en_HK
dc.format.extent190114 bytes-
dc.format.extent28672 bytes-
dc.format.extent4936 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/msword-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/en_HK
dc.relation.ispartofGuten_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsGut. Copyright © B M J Publishing Group.en_HK
dc.subject.meshAnti-bacterial agents - adverse effects - therapeutic useen_HK
dc.subject.meshAnti-ulcer agents - therapeutic useen_HK
dc.subject.meshDyspepsia - complications - drug therapy - microbiologyen_HK
dc.subject.meshOmeprazole - adverse effects - analogs & derivatives - therapeutic useen_HK
dc.subject.meshHelicobacter infections - complicationsen_HK
dc.titleDouble blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0017-5749&volume=51&issue=4&spage=502&epage=506&date=2002&atitle=Double+blind,+randomised,+placebo+controlled+study+of+four+weeks+of+lansoprazole+for+the+treatment+of+functional+dyspepsia+in+Chinese+patientsen_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1136/gut.51.4.502en_HK
dc.identifier.pmid12235071-
dc.identifier.pmcidPMC1773405-
dc.identifier.scopuseid_2-s2.0-0036785324en_HK
dc.identifier.hkuros82278-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036785324&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume51en_HK
dc.identifier.issue4en_HK
dc.identifier.spage502en_HK
dc.identifier.epage506en_HK
dc.identifier.isiWOS:000178243600012-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridHung, WK=26027012100en_HK
dc.identifier.scopusauthoridYee, YK=7004400469en_HK
dc.identifier.scopusauthoridYip, AWC=7004871369en_HK
dc.identifier.scopusauthoridSzeto, ML=6602526385en_HK
dc.identifier.scopusauthoridFung, FMY=7003833944en_HK
dc.identifier.scopusauthoridTong, TSM=7102587364en_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridHu, WHC=25932937100en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats